Free Trial

20 Stocks to Sell Now - 14 of 20

 
 

Ginkgo Bioworks (NYSE:DNA)

Consensus Rating
Reduce
Rating Score
1.7
Ratings Breakdown
1 Buy Ratings, 2 Hold Ratings, 3 Sell Ratings.
Consensus Price Target
$3.42 (57.8% Downside)

About Ginkgo Bioworks

Ginkgo Bioworks logoGinkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/20/2024TD CowenBoost Price TargetBuy ➝ Buy$3.00 ➝ $10.00
8/23/2024BTIG ResearchBoost Price TargetSell ➝ Sell$0.20 ➝ $7.00
7/9/2024The Goldman Sachs GroupLower Price TargetSell ➝ Sell$0.02 ➝ $0.01
6/26/2024BTIG ResearchLower Price TargetSell ➝ Sell$0.01 ➝ $0.01
5/15/2024Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$0.05 ➝ $0.03
5/15/2024BTIG ResearchDowngradeNeutral ➝ Sell
5/10/2024William BlairDowngradeMarket Perform ➝ Underperform
3/1/2024TD CowenLower Price TargetOutperform ➝ Outperform$0.18 ➝ $0.08
1/22/2024The Goldman Sachs GroupLower Price TargetSell ➝ Sell$0.03 ➝ $0.03
11/14/2023Raymond JamesDowngradeOutperform ➝ Market Perform$0.09 ➝ $0.06
 

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>